Doi, Toshihiko
Aramaki, Takeshi
Yasui, Hirofumi
Muro, Kei
Ikeda, Masafumi
Okusaka, Takuji
Inaba, Yoshitaka
Nakai, Kenya
Ikezawa, Hiroki
Nakajima, Ryo
Funding for this research was provided by:
Eisai (N/A)
Article History
Received: 31 October 2018
Accepted: 10 December 2018
First Online: 9 January 2019
Compliance with ethical standards
:
: T.D. has received consultancy fees from Eli Lilly, Chugai Pharmaceutical, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Amgen, Sumitomo Dainippon Pharma, and Taiho Pharmaceutical; and research grants from Taiho Pharmaceutical, Novartis, Merck Serono, Astellas Pharma, MSD, Janssen, Boehringer Ingelheim, Takeda Pharmaceutical, Pfizer, Eli Lilly, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Kyowa Hakko Kirin, Daiichi Sankyo, Celgene, Bristol-Myers Squibb, AbbVie, and Quintiles.T.A. has received lecture fees from Canon Medical Systems, Terumo, Eisai, Otsuka Pharmaceutical, and Nihon Kayaku.H.Y. has no conflicts of interest to declare.K.M. has received consultancy fees from Eli Lilly and Ono Pharmaceutical; lecture fees from Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Yakult Honsha, Bayer Yakuhin, and Merck Serono; and research grants from Gilead, Kyowa Hakko Kirin, Daiichi Sankyo, Pfizer, MSD, Shionogi, Ono Pharmaceutical, and Merck Serono.M.I. has received consultancy fees from NanoCarrier, Bayer Yakuhin, Eisai, Kyowa Hakko Kirin, Novartis, Shire, Bristol-Myers Squibb, MSD, Teijin Pharma, Daiichi Sankyo, and Eli Lilly; lecture fees from Novartis, Bayer Yakuhin, Bristol-Myers Squibb, Abbott, Eisai, Taiho Pharmaceutical, Eli Lilly, Yakult Honsha, Otsuka Pharmaceutical, Daiichi Sankyo, Chugai Pharmaceutical, Nobelpharma, Sumitomo Dainippon Pharma, and Teijin Pharma; and research grants from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult Honsha, Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Eisai, AstraZeneca, Baxalta, Chugai Pharmaceutical, Bristol-Myers Squibb, Zeria Pharmaceutical, Boehringer Ingelheim, Merck Serono, Kowa, NanoCarrier, Aslan Pharmaceuticals, Novartis, and Takara Bio.T.O. has received consultancy fees from Taiho Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, and Zeria Pharmaceutical; lecture fees from Eli Lilly, AstraZeneca, Chugai Pharmaceutical, Eisai, Novartis, Daiichi Sankyo, FUJIFILM RI Pharma, Ono Pharmaceutical, Yakult Honsha, Shire, EA Pharma, Teijin Pharma, Pfizer, Nobelpharma, Bayer Yakuhin, AbbVie, and Taiho Pharmaceutical; manuscript writing/editing fees from Medical Review, Shogakukan Creative, Fuki Shobo, Arc Medium, Mainichi Shimbun Publishing, Kagakuhyoronsha, and Igaku-Shoin; and research grants from Kowa, Novartis, Pfizer, Eisai, Yakult Honsha, Bayer Yakuhin, Ono Pharmaceutical, Kyowa Hakko Kirin, Taiho Pharmaceutical, Sumitomo Dainippon Pharma, Eli Lilly, AstraZeneca, Chugai Pharmaceutical, NanoCarrier, and Baxalta.Y.I. has received consultancy fees from Eisai and Medicon; lecture fees from Bayer Yakuhin, Medicon, Fuji Pharma, Shionogi, Eisai, Teijin Pharma, Canon Medical Systems, Toray Medical, FUJIFILM RI Pharma, Otsuka Pharmaceutical, and Nippon Kayaku; and manuscript writing/editing fees from Guerbet, Eisai, and Bayer Yakuhin; and research grants from Eisai, Kyowa Hakko Kirin, Astellas Pharma, and Pfizer.K.N., H.I., and R.N. are employees of Eisai.
: All procedures performed in studies involving human participants were in accordance with ethical standards of the relevant Institutional Review Boards, the 1964 Helsinki declaration and its later amendments, and the Pharmaceutical Affairs Law of Japan. This article does not contain any studies with animals performed by any of the authors. The study protocol was approved by the Medical Ethics Committees of the participating institutions.
: Informed consent was obtained from all individual participants included in the study.